EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction

Maria Gnarra Beuthe, Kristen Kahle, James Treat, Denise Adams, Sally Cohen-Cutler, Michael Kelly, Megha Tollefson, Amy Theos, Jeffrey Martini, Wes Kaupinen, Emily Cook, Andrea Zaenglein und 7 weitere

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s823

DOI: 10.25251/3ggsk832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Maria Gnarra Beuthe und 18 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Microcystic lymphatic malformations (mLM) are lifelong, rare, and serious vascular anomalies associated with substantial physical and psychosocial morbidity. Currently, no FDA-approved therapeutics exist; disease management involves invasive procedures (surgery, sclerotherapy, laser) and off-label oral and topical sirolimus, all associated with inconsistent results. Sirolimus topical gel 3.9%, developed on the QTORIN™ platform to address these unmet therapeutic needs, was evaluated in the pivotal Phase 3 SELVA trial. Consistent with regulatory guidance emphasizing the patient voice in drug development, an embedded qualitative interview study characterized patient/caregiver perspectives of mLM and the meaningfulness of treatment-related change.

Objective

To contextualize clinical trial efficacy endpoints through the patient/caregiver experience and evaluate treatment satisfaction following topical sirolimus 3.9% gel.

Methods

Semi-structured entry (baseline) and exit (Day 168) interviews were conducted with trial participants and/or their caregivers (for participants

Zitieren

APA

Beuthe, M. G., Kahle, K., Treat, J., Adams, D., Cohen-Cutler, S., Kelly, M., Tollefson, M., Theos, A., Martini, J., Kaupinen, W., Cook, E., Zaenglein, A., Ricci, K., Nieman, E., Iacobas, I., White, M., Swaminathan, N., Hudgens, S., & Teng, J. (2026). Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction. SKIN The Journal of Cutaneous Medicine, 10(6), s823. https://doi.org/10.25251/3ggsk832

Vancouver

Beuthe MG, Kahle K, Treat J, Adams D, Cohen-Cutler S, Kelly M, et al. Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s823. doi:10.25251/3ggsk832

BibTeX
@article{Beuthe2026,
  author = {Beuthe, Maria Gnarra and Kahle, Kristen and Treat, James and Adams, Denise and Cohen-Cutler, Sally and Kelly, Michael and Tollefson, Megha and Theos, Amy and Martini, Jeffrey and Kaupinen, Wes and Cook, Emily and Zaenglein, Andrea and Ricci, Kiersten and Nieman, Elizabeth and Iacobas, Ionela and White, Michael and Swaminathan, Neeraja and Hudgens, Stacie and Teng, Joyce},
  title = {Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s823},
  doi = {10.25251/3ggsk832}
}
Kostenlos starten →